Cardiolipin-Based Nanoparticles Inhibit α-Synuclein Fibrilization

ACS Chem Neurosci. 2026 Jan 7;17(1):150-159. doi: 10.1021/acschemneuro.5c00688. Epub 2025 Dec 26.

Abstract

Synucleinopathies are a group of neurodegenerative disorders characterized by structural aberrations in the protein alpha-synuclein (α-syn). In these disorders, α-syn accumulates and misfolds, contributing to the formation of intracellular inclusion bodies believed to precede cellular death. We investigated the capacity of cardiolipin (CL)-based nanoparticles to reverse α-syn fibrillization, and rescue loss of dopamine neurons. Using circular dichroism (CD) and transmission electron microscopy (TEM), we assessed conformational changes in α-syn upon interaction with CL-nanoparticles. Combined with functional assessment of CL-nanoparticles in rodent models of synucleinopathy, we demonstrate that CL nanoparticles induced structural refolding of fibrillar α-syn toward a monomeric α-helical form, dissolving α-syn aggregates and rescuing from cell death. Thus, CL-based nanoparticles may represent a therapeutic tool to mitigate synucleinopathy.

Keywords: alpha-synuclein (α-synuclein); cardiolipin; lipid nanoparticles; neuron; protein structure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cardiolipins* / pharmacology
  • Dopaminergic Neurons / drug effects
  • Dopaminergic Neurons / metabolism
  • Humans
  • Mice
  • Nanoparticles* / chemistry
  • Rats
  • Synucleinopathies* / drug therapy
  • Synucleinopathies* / metabolism
  • alpha-Synuclein* / drug effects
  • alpha-Synuclein* / metabolism

Substances

  • alpha-Synuclein
  • Cardiolipins